{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-204982","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.892911+00:00","generated_at":"2026-05-14T23:43:17.741472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pediatrix Q1 GAAP EPS $0.36, Adj. EPS $0.44; revenue $476M, beat expectations","bullets":["Net revenue $476.2M, up 4% YoY from $458.4M; same-unit revenue grew 2.8%.","Adjusted EBITDA $58.2M vs $49.2M YoY; net income $29.6M ($0.36 diluted) vs $20.7M ($0.24).","Same-unit volume down 1.6% (hospital services -1.5%, office -3.3%) but reimbursement up 4.4%.","Reaffirmed FY2026 Adjusted EBITDA guidance range of $280M-$300M.","Used $21.5M for share repurchases and $7.0M for acquisitions in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-204982","json":"https://secwatch.observer/filing/0001193125-26-204982.json","markdown":"https://secwatch.observer/filing/0001193125-26-204982.md","text":"https://secwatch.observer/filing/0001193125-26-204982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000119312526204982/0001193125-26-204982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000119312526204982/md-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:43:17.741472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b7c3d410984b70ba01f2fa569f2780df2f5aea7","claim":"Pediatrix Medical Group, Inc. reported three months ended March 31, 2026 results: revenue $476 million, net income $30 million, EPS $0.36 per share. Guidance reaffirmed.","evidence_excerpt":"ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2026 first quarter, Pediatrix reported the following results: • Net revenue of $476 million; • Net income of $30 million; and • Adjusted EBITDA of $58 million. “Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000119312526204982/0001193125-26-204982-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Revenue","value":"$476 million"},{"label":"Net income","value":"$30 million"},{"label":"EPS","value":"$0.36 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}